Ozanimod
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Ozanimod (Celgene) is a sphingosine 1-phosphate (S1P) receptor agonist, with selectivity for the sphingosine 1-phosphate type 1 receptor (S1P1) and sphingosine 1-phosphate receptor 5 (S1P5). The drug modulates the expression of S1P receptors, which is thought to reduce the overall number of circulating lymphocytes by preventing their migration from secondary lymphoid organs. The drug is being developed in multiple sclerosis, ulcerative colitis, and Crohn’s disease.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 ozanimod : Crohn’s disease
18 ozanimod : Multiple sclerosis (MS)
27 ozanimod : Ulcerative colitis
LIST OF FIGURES
11 Figure 29: Datamonitor Healthcare’s drug assessment summary of etrolizumab in Crohn’s disease
12 Figure 6: Datamonitor Healthcare’s drug assessment summary of filgotinib in Crohn’s disease
20 Figure 23: Datamonitor Healthcare’s drug assessment summary of Stelara in Crohn’s disease
21 Figure 23: Datamonitor Healthcare’s drug assessment summary of Stelara in Crohn’s disease
23 Figure 31: Etrolizumab for Crohn’s disease – SWOT analysis
30 Figure 34: Ozanimod for Crohn’s disease – SWOT analysis
31 Figure 6: Datamonitor Healthcare’s drug assessment summary of ozanimod in Crohn’s disease
32 Figure 27: Tysabri sales for Crohn’s disease in the US, 2016–25
LIST OF TABLES
6 Table 1: Ozanimod drug profile
7 Table 2: Ozanimod Phase III trials in Crohn’s disease
10 Table 3: Ozanimod Phase II data in Crohn’s disease
19 Table 4: Ozanimod drug profile
25 Table 28: Tysabri pivotal trial data in Crohn’s disease
26 Table 6: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016–25
28 Table 7: Ozanimod drug profile
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Remicade 
Sign up to the